These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33664520)

  • 1. Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
    Wang L; Shao X; Zhong T; Wu Y; Xu A; Sun X; Gao H; Liu Y; Lan T; Tong Y; Tao X; Du W; Wang W; Chen Y; Li T; Meng X; Deng H; Yang B; He Q; Ying M; Rao Y
    Nat Chem Biol; 2021 May; 17(5):567-575. PubMed ID: 33664520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML.
    Wu M; Wang W; Mao X; Wu Y; Jin Y; Liu T; Lu Y; Dai H; Zeng S; Huang W; Wang Y; Yao X; Che J; Ying M; Dong X
    Eur J Med Chem; 2024 Sep; 275():116539. PubMed ID: 38878515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2.
    Ying M; Shao X; Jing H; Liu Y; Qi X; Cao J; Chen Y; Xiang S; Song H; Hu R; Wei G; Yang B; He Q
    Blood; 2018 Jun; 131(24):2698-2711. PubMed ID: 29720484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK2 suppression synergizes with all-trans-retinoic acid to overcome the myeloid differentiation blockade of AML cells.
    Shao X; Xiang S; Fu H; Chen Y; Xu A; Liu Y; Qi X; Cao J; Zhu H; Yang B; He Q; Ying M
    Pharmacol Res; 2020 Jan; 151():104545. PubMed ID: 31740384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2.
    Lin Y; Li D; Liang Q; Liu S; Zuo X; Li L; Sun X; Li W; Guo M; Huang Z
    J Biol Chem; 2015 Jan; 290(3):1818-28. PubMed ID: 25451924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells.
    Yang J; Lan J; Du H; Zhang X; Li A; Zhang X; Liu Y; Zhang J; Zhang C; Ding Y; Zhang T
    Eur J Pharmacol; 2019 Mar; 846():12-22. PubMed ID: 30579933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss.
    Hati S; Zallocchi M; Hazlitt R; Li Y; Vijayakumar S; Min J; Rankovic Z; Lovas S; Zuo J
    Eur J Med Chem; 2021 Dec; 226():113849. PubMed ID: 34560429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK2-instigates C/EBPα degradation through SKP2 in Acute myeloid leukemia.
    Thacker G; Mishra M; Sharma A; Singh AK; Sanyal S; Trivedi AK
    Med Oncol; 2021 May; 38(6):69. PubMed ID: 34002296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
    PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirement for LIM kinases in acute myeloid leukemia.
    Jensen P; Carlet M; Schlenk RF; Weber A; Kress J; Brunner I; Słabicki M; Grill G; Weisemann S; Cheng YY; Jeremias I; Scholl C; Fröhling S
    Leukemia; 2020 Dec; 34(12):3173-3185. PubMed ID: 32591645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of celecoxib and doxorubicin increases growth inhibition and apoptosis in acute myeloid leukemia cells.
    Chen C; Xu W; Wang CM
    Leuk Lymphoma; 2013 Nov; 54(11):2517-22. PubMed ID: 23452119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic and genetic approaches identify Syk as an AML target.
    Hahn CK; Berchuck JE; Ross KN; Kakoza RM; Clauser K; Schinzel AC; Ross L; Galinsky I; Davis TN; Silver SJ; Root DE; Stone RM; DeAngelo DJ; Carroll M; Hahn WC; Carr SA; Golub TR; Kung AL; Stegmaier K
    Cancer Cell; 2009 Oct; 16(4):281-94. PubMed ID: 19800574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.
    De Luca L; Trino S; Laurenzana I; Tagliaferri D; Falco G; Grieco V; Bianchino G; Nozza F; Campia V; D'Alessio F; La Rocca F; Caivano A; Villani O; Cilloni D; Musto P; Del Vecchio L
    Cell Death Dis; 2017 Jun; 8(6):e2849. PubMed ID: 28569789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells.
    Leontovich AA; Salisbury JL; Veroux M; Tallarita T; Billadeau D; McCubrey J; Ingle J; Galanis E; D'Assoro AB
    Oncol Rep; 2013 May; 29(5):1785-8. PubMed ID: 23446853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors and PROTACs of CDK2: challenges and opportunities.
    Zeng Y; Ren X; Jin P; Fan Z; Liu M; Zhang Y; Li L; Zhuo M; Wang J; Li Z; Wu M
    Expert Opin Drug Discov; 2024 Sep; 19(9):1125-1148. PubMed ID: 38994606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia.
    Qi J; Gao X; Zhong X; Zhang N; Wang R; Zhang H; Pan T; Liu X; Yao Y; Wu Q; Niu M; Xu K
    Biomed Pharmacother; 2019 Sep; 117():109113. PubMed ID: 31207577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
    Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
    Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.